Liver Disease and Transplantation

Moved, week to 23 Oct 2026: 1
Papers in 60 days: 22

Add Liver Disease and Transplantation as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest

Rebuilt 23 October 2026 at 1:59 pm AEDT

Moved this week

Everything that moved →

Ammonia measurement in cirrhosis: International Delphi consensus recommendations from ISHEN.
Journal of hepatology · 1 Aug 2026 · Consensus Statement
Read the AI summary in JClub
- Open access
- 9 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41865800
Open in JClub

Latest in Liver Disease and Transplantation

Newest first · last 60 days

Cirrhosis-associated immune dysfunction reflects impaired intestinal CD8ab⁺ intraepithelial lymphocyte compartmentalization
bioRxiv · 14 Oct 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.03.26.713594
Open in JClub
Serum thrombospondin-2 as a non-invasive biomarker for liver fibrosis in chronic hepatitis B.
Gut · 7 Oct 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41407527
Open in JClub
How accurate is EUS-guided direct portal vein pressure measurement? A comparison with intraoperative measurements.
Gut · 7 Oct 2026 · Journal Article
Read the AI summary in JClub
- 3 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/40701791
Open in JClub
Closing the policy gap: including children in the global agenda for steatotic liver disease.
Nature reviews. Gastroenterology & hepatology · 1 Oct 2026 · Letter
Read the AI summary in JClub
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42649274
Open in JClub
A Neutrophil Defensin-VDAC1 Axis Drives Steatotic Liver Disease
bioRxiv · 28 Sept 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.09.19.752841
Open in JClub
Characteristics associated with culture-positivity versus antibiotic administration in patients with cirrhosis on ICU admission: a retrospective cohort study in 5 hospitals.
medRxiv · 24 Sept 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.09.22.26363729
Open in JClub
Missingness-aware machine learning using routine laboratory data for distinguishing hepatitis from cirrhosis.
Frontiers in Genetics · 22 Sept 2026 · Journal Article
Missingness-aware machine learning models using routine lab data achieve significantly higher discrimination of cirrhosis among hepatitis patients, with AUC up to 0.841.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42835859
Open in JClub
Sustained Safety and Efficacy of Entecavir Monotherapy for Chronic Hepatitis B After Liver Transplantation: 15-Year Follow-Up.
Gastroenterology · 21 Sept 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42767282
Open in JClub
Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework.
Nature reviews. Gastroenterology & hepatology · 9 Sept 2026 · Review
Multidisciplinary heart-liver co-management improves detection and treatment of MASLD, addressing a critical gap in cardiometabolic care with potential to reduce mortality.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42717057
Open in JClub
When the vascular lining loosens, dysfunctional macrophages permit pathological bacterial translocation in cirrhosis.
Gut · 7 Sept 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41482457
Open in JClub
Intestinal blood vessel-associated macrophages and gut-vascular barrier dysfunction in cirrhosis.
Gut · 7 Sept 2026 · Journal Article
Vascular macrophage dysfunction causes bacterial translocation in cirrhosis, with 20-week murine models showing impaired gut-vascular interactions and increased systemic bacterial spread.
- Open access
- 10 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41253495
Open in JClub
New frontier in albumin replacement therapy.
Gut · 7 Sept 2026 · Journal Article
Read the AI summary in JClub
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/40695621
Open in JClub
Response to: Beyond gastrointestinal symptom burden: exploring the impact of previous cholecystectomy on ultrasound-based hepatocellular carcinoma surveillance in patients with liver cirrhosis.
Gut · 4 Sept 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42697714
Open in JClub
The role of primary care in response to the global liver disease syndemic: a Lancet Gastroenterology & Hepatology Commission.
The lancet. Gastroenterology & hepatology · 1 Sept 2026 · Review
Read the AI summary in JClub
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42385752
Open in JClub
Spleen stiffness measurement rules out high-risk varices in patients with chronic portal vein thrombosis without cirrhosis.
Journal of hepatology · 1 Sept 2026 · Journal Article
Spleen stiffness measurement ≤40 kPa accurately rules out high-risk varices in patients with chronic portal vein thrombosis without cirrhosis, enabling endoscopy sparing.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42679862
Open in JClub
Therapeutic drift or formulation drift: avoiding misconceptions about rifaximin and antimicrobial resistance in cirrhosis.
The lancet. Gastroenterology & hepatology · 1 Sept 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42556367
Open in JClub
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.
The lancet. Gastroenterology & hepatology · 1 Sept 2026 · Randomized Controlled Trial
Semaglutide 2·4 mg significantly improved liver fibrosis without worsening steatohepatitis in patients with fibrosis and cirrhosis, unlike the zalfermin combination.
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42456707
Open in JClub
Steatotic liver disease in Latin America: current views and perspectives.
Nature reviews. Gastroenterology & hepatology · 1 Sept 2026 · Review
Latin America faces a high and rising burden of steatotic liver disease driven by obesity, alcohol use, and genetic factors, with significant health system challenges.
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42298140
Open in JClub
Uncovering immune dysfunction in ACLF: Cellular mechanisms, molecular pathways, and therapeutic frontiers.
Journal of hepatology · 1 Sept 2026 · Review
Read the AI summary in JClub
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42067150
Open in JClub
Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acid.
Journal of hepatology · 1 Sept 2026 · Journal Article
Read the AI summary in JClub
- 2 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42119851
Open in JClub
Histology alone may underestimate liver cirrhosis despite adequate biopsy quality: evidence from minilaparoscopic liver biopsies.
Journal of hepatology · 27 Aug 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42660234
Open in JClub
From pressure to prognosis: establishing a common language for portal hypertension in advanced chronic liver disease.
Gut · 25 Aug 2026 · Journal Article
Non-invasive tests can predict decompensation risk in advanced liver disease as accurately as HVPG, enabling personalized prognosis and management.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42642217
Open in JClub

Add Liver Disease and Transplantation as an interest in JClub

Journals this month

All journals →

Topics moving, week to 23 Oct 2026

All topics →

By field

All journals by field →

Moved this week

Latest in Liver Disease and Transplantation

Browse JClub